Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

CLICK HERE FOR CME CREDIT

Since you and others at Yale have treated a number of patients with scleroderma—and other conditions—with ECP, can you share your real world clinical experience with this treatment modality? And how measure clinical response to this therapy?

Created by

CMEducation Resources IQ&A Extracorporeal Photopheresis Intelligence Zone | The Multi-Specialty Perspective

Presenter

Ian Odell, MD, PhD

Ian Odell, MD, PhD

Ian Odell, MD, PhD
Assistant Professor
Dermatology Director, Adult Primary Care Center
Scleroderma and Myositis Program
Yale University School of Medicine